Table 2.

Clinical characteristics of Anti-RNPC3 positive and negative patients in the confirmation study (University of Pittsburgh Scleroderma Cohort)

Variable	Anti-RNPC3 positive (n=39)	Anti-RNPC3 negative (n=117)	P-value
Age, year	47.1 ± 13.4	52.4 ± 14.8	0.05
Male, %	31	15	0.04
Black race, %	18	6	0.02
Cutaneous subtype, diffuse,^ %	56	44	0.17
Disease duration, yrs *┼	3.1 (2.0, 5.7)	4.4 (1.1, 14.0)’d ju	0.91
Moderate to severe GI disease, %	36	15	<0.01
Interstitial lung disease, %	77	35	<0.01
Skeletal myopathy,^ %	5	14	0.15
Minimum FVC, %predicted (n)	66.8 ± 22.2 (38)	76.3 ± 21.0 (82)	0.03

n= number; SD = standard deviation; IQR = interquartile range; GI = gastrointestinal; FVC = forced vital capacity; yrs = years;

^┼disease duration from any first symptom to first visit